Cytokinetics.
company in South San Francisco, United States
- Reports this week
- 4
- Active events
- 3
- Connections
- 67
What's happening
Active this week
-
Sung Lee became EVP at Cytokinetics, and Bank of Montreal increased its holdings in the company.Well supported4 reports
-
Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.Some support3 reports
-
MarketBeat reported analyst ratings for Maze Therapeutics, which utilizes the Compass platform, highlighting competition among healthcare companies.Some support1 report
Earlier this month
-
MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.Some support1 report
-
Analysts upgraded stock ratings for several companies, including GCT, Cytokinetics, and Cadence Design Systems, on October 12, 2026.Some support1 report
-
Healthcare companies Cytokinetics and Pluri Inc. are competing for investment funding.Some support1 report
-
Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.Well supported10 reports
One to three months ago
-
The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.Some support3 reports1 development inside
-
Product Myqorzo received FDA approval.Some support1 report
-
Leerink and Stifel analysts commented on efficacy data following the separation of Myqorzo from the Camzyos market.Some support1 report
Gone quiet
No new reports in 90+ days-
Cytokinetics filed required disclosures with the SEC under a Rule 10b5-1 trading plan on June 23, 2026.Some support2 reports
-
MarketBeat is aggregating consensus ratings for Cytokinetics, while Bank of America provided a neutral rating and Morgan Stanley raised its target price.Some support2 reports
-
Cytokinetics is based in South San Francisco.Some support1 report
-
Cytokinetics achieved the first commercial launch of its drug in Germany, enabled by approval from the European Commission.Some support1 report
-
Yasmeen Rahimi maintained a Buy rating on Cytokinetics on July 6, 2025.Speculative1 report
-
Cytokinetics announced a revenue forecast growth of 54% per annum.Some support1 report
-
A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.Some support1 report
-
Cytokinetics complied with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants on August 20, 2025.Some support3 reports
-
Rezolute, Inc. appointed Sunil Karnawat as Chief Commercial Officer, following his previous roles at Cytokinetics, Novo Nordisk, and Johnson & Johnson.Some support1 report
-
Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.Some support1 report
-
Cytokinetics management attended a conference on August 28, 2025, in both Boston and Everett.Some support1 report
-
Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.Some support1 report1 development inside
-
Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.Some support1 report
-
Cytokinetics presented study results at the European Society of Cardiology Congress in Madrid, Spain.Well supported6 reports
-
The new event details several corporate developments, including mergers involving Air Lease and Apollo, and Elliott Management's stake acquisition in PepsiCo.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Cytokinetics this week
News at the entities that move Cytokinetics most-
FDA StructuralThe FDA has listed recalled products, involving the company Colgate.Moves Cytokinetics
-
Morgan Stanley OperationalMicron Technology, Norges Bank, and Morgan Stanley are involved in stock purchases and increased holdings as of June 26, 2026, requiring SEC filings.Moves Cytokinetics
-
SEC StructuralCrane filed reports with the SEC and James Tullis was identified as a director of the company.Moves Cytokinetics
-
Securities and Exchange Commission StructuralThe SEC is tracking 13F filings submitted by institutional investors, involving Omnicom Group.Moves Cytokinetics
-
EMA StructuralEMA provided updates to businesses in New Zealand on January 1, 2026.Moves Cytokinetics
-
European Commission StructuralCampaigners are demanding binding reforms through the Parliament.Moves Cytokinetics
Connections
The 26 strongest of 67, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
representative Transactional
Representative purchased shares of Cytokinetics.
-
SEC Structural
Cytokinetics must comply with SEC regulations, specifically regarding Rule 10b5-1 trading plans.
-
Sung Lee Structural
Sung Lee serves as the Executive Vice President of Cytokinetics.
-
FDA Structural
Cytokinetics' commercial viability is formally dependent on the review, approval, and oversight of its products by the FDA.
-
Securities and Exchange Commission Structural
Cytokinetics is subject to formal regulatory requirements and compliance oversight by the Securities and Exchange Commission.
-
Bristol-Myers Squibb Operational
The companies are direct competitors in the development and market presence of medicines for Hypertrophic Cardiomyopathy (HCM).
-
EMA Structural
Cytokinetics is actively seeking marketing authorization from the EMA.
-
Gil Cisneros Transactional
Gil Cisneros purchased shares of Cytokinetics.
Show all 26 connections
-
Morgan Stanley Operational
Morgan Stanley raised its target price for Cytokinetics stock, signaling market confidence in Cytokinetics' value.
-
European Commission Structural
The European Commission's regulatory approval enables Cytokinetics' market entry into Europe.
-
Pluri Inc. Operational
Cytokinetics and Pluri Inc. are active competitors within the healthcare sector, vying for investment.
-
Nasdaq Structural
Cytokinetics is formally listed on the Nasdaq exchange, making its public function dependent on the platform.
-
Truist Financial Operational
Truist Financial provided a buy rating and increased the price target for Cytokinetics.
-
Bank of Montreal Transactional
Bank of Montreal raised its investment holdings in Cytokinetics.
-
Royal Bank of Canada Mentioned together
Royal Bank of Canada provides financial analysis and price targets for Cytokinetics shares.
-
MarketBeat Mentioned together
MarketBeat aggregates and reports analyst recommendations and performance analysis regarding Cytokinetics.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald issued an overweight investment rating on Cytokinetics.
-
Revvity Mentioned together
Both Revvity and Cytokinetics are identified as publicly traded biotech companies.
-
Spain Shared context
Cytokinetics conducted presentations and announced data at a congress held in Spain.
-
European Society of Cardiology Mentioned together
Cytokinetics utilizes the European Society of Cardiology as a platform to present clinical trial results and investor updates.
-
South San Francisco Shared context
Cytokinetics is geographically situated in South San Francisco.
-
Stifel Mentioned together
Stifel provides market commentary and analysis regarding Cytokinetics' stock performance and clinical data.
-
Europe Structural
Cytokinetics is gaining regulatory approval and establishing market presence in Europe.
-
Bank of America Mentioned together
Bank of America provided a neutral rating on Cytokinetics shares.
-
Needham & Company Mentioned together
Needham & Company provided a buy rating and increased the target price for Cytokinetics.
-
Novartis Transactional
Novartis is identified as a potential buyer of Cytokinetics' Myqorzo asset.
History
Events by the month they beganOctober 2026
4 events- MarketBeat reported analyst ratings for Maze Therapeutics, which utilizes the Compass platform, highlighting competition among healthcare companies.
- MarketBeat reported analyst recommendations for Cytokinetics and Gain Therapeutics, two competing healthcare companies.
- Analysts upgraded stock ratings for several companies, including GCT, Cytokinetics, and Cadence Design Systems, on October 12, 2026.
- Healthcare companies Cytokinetics and Pluri Inc. are competing for investment funding.
September 2026
1 eventAugust 2026
1 eventShow 2 earlier months
July 2026
1 eventJune 2026
18 events- Zymeworks and Cytokinetics are companies operating in the medical/biomedical sector.
- Price targets for UDR were adjusted by Cantor Fitzgerald, Scotiabank, and Royal Bank of Canada on May 26, 2026.
- The FDA has approved a drug developed by Cytokinetics for its intended use as a treatment.
- Cytokinetics filed required disclosures with the SEC under a Rule 10b5-1 trading plan on June 23, 2026.
- MarketBeat is aggregating consensus ratings for Cytokinetics, while Bank of America provided a neutral rating and Morgan Stanley raised its target price.
- Cytokinetics is based in South San Francisco.
- Cytokinetics achieved the first commercial launch of its drug in Germany, enabled by approval from the European Commission.
- Yasmeen Rahimi maintained a Buy rating on Cytokinetics on July 6, 2025.
- Cytokinetics announced a revenue forecast growth of 54% per annum.
- A career profile of James M. Daly detailing his appointments at Cytokinetics, Amgen, and GlaxoSmithKline.
- Cytokinetics complied with Nasdaq Listing Rule 5635(c)(4) regarding inducement grants on August 20, 2025.
- Rezolute, Inc. appointed Sunil Karnawat as Chief Commercial Officer, following his previous roles at Cytokinetics, Novo Nordisk, and Johnson & Johnson.
- Cytokinetics and Pfizer announced strong US sales growth for Camzyos and a co-development agreement for Eliquis.
- Cytokinetics management attended a conference on August 28, 2025, in both Boston and Everett.
- Cytokinetics' drug is under FDA review, with clinical data presented at a congress in Madrid, Spain.
- Cytokinetics developed and tested Aficamten, finding it superior to Metoprolol and calling into question reliance on beta-blockers.
- Cytokinetics presented study results at the European Society of Cardiology Congress in Madrid, Spain.
- The new event details several corporate developments, including mergers involving Air Lease and Apollo, and Elliott Management's stake acquisition in PepsiCo.